Return to homepagePandemic Pact

CORONA - Parmenides - DIRECT-Dx - TP2

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 03COV24B

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $834,998.11

  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)

  • Principal Investigator

    Erik Schliebs

  • Research Location

    Germany

  • Lead Research Institution

    preclinics Gesellschaft für Präklinische Forschung mbH

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Within the framework of the joint project "DIRECT-Dx", antibodies directed against the SARS-CoV-2 virus are to be developed, which will serve as the basis for a new rapid test procedure. Compared to other diagnostics, such antibody-based direct detections indicate the intact and therefore infectious virus. With the aid of this test procedure, the alliance hopes to create an effective means of rapidly detecting any infections and thus isolating sources of infection at an early stage. A simple detection system, e.g. in the form of a color change or a strip test, is to be developed. In addition to simple handling, such an antibody-based detection method also offers the possibility of obtaining timely on-site results.